Last reviewed · How we verify
NCT02921126: RE-FIT
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
trial in Anticoagulation in 9,914 participants. Completed in 2 August 2018.
2 August 2018
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9,914 |
| Start date | 30 April 2017 |
| Primary completion | 2 August 2018 |
| Estimated completion | 2 August 2018 |
| Sites | 1 location across Italy |
Conditions studied
- Anticoagulation — all drugs for Anticoagulation →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Anticoagulation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02921126
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anticoagulation
Currently open trials in the same condition.
- NCT05782270 — Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy · Phase 4 · recruiting
- NCT07129395 — Anticoagulation Adherence Measurement Strategies · active not recruiting
- NCT04539301 — Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux L · recruiting
- NCT03910933 — Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative · active not recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02921126 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 8 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02921126.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing